Clinical Trial Update: Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy; the trial is sponsored by NMD Pharm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• NMD670

Snippet

Sponsor: NMD Pharma A/S | Conditions: Spinal Muscular Atrophy | Phase 2 | Status: ACTIVE_NOT_RECRUITING